PTJ
KROS icon

Paul Tudor Jones’s Keros Therapeutics KROS Stock Holding History

Paul Tudor Jones’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,007
Closed -$309K – 3946
2026
Q1 		$309K Sell
28,007
-300
-1% -$4.63K ﹤0.01% 3118
2025
Q4 		$576K Buy
28,307
+8,782
+45% +$154K ﹤0.01% 2639
2025
Q3 		$309K Buy
+19,525
New +$288K ﹤0.01% 2959
2025
Q2 		– Sell
-19,858
Closed -$202K – 3521
2025
Q1 		$202K Buy
19,858
+4,527
+30% +$52.6K ﹤0.01% 2863
2024
Q4 		$243K Sell
15,331
-4,456
-23% -$232K ﹤0.01% 2723
2024
Q3 		$1.15M Buy
19,787
+9,430
+91% +$466K ﹤0.01% 1533
2024
Q2 		$473K Sell
10,357
-6,646
-39% -$357K ﹤0.01% 1829
2024
Q1 		$1.13M Buy
17,003
+7,560
+80% +$448K 0.01% 1276
2023
Q4 		$375K Buy
+9,443
New +$296K ﹤0.01% 1935
2023
Q2 		– Sell
-17,666
Closed -$754K – 2705
2023
Q1 		$754K Buy
+17,666
New +$892K 0.01% 1374
2022
Q4 		– Sell
-12,829
Closed -$483K – 2641
2022
Q3 		$483K Buy
12,829
+636
+5% +$22K 0.01% 1429
2022
Q2 		$337K Buy
+12,193
New +$535K 0.01% 1490

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Paul Tudor Jones's KROS Position: Q2 2026 in Review

Paul Tudor Jones sold out of Keros Therapeutics (KROS) in Q2 2026, closing a stake of 28,007 shares — an estimated $309K sold.

Paul Tudor Jones first reported a position in KROS in Q2 2022 and held it in 12 quarters. The position peaked at $1.15M in Q3 2024. 131 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Paul Tudor Jones reported no remaining Keros Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 28,007 Keros Therapeutics shares in Q2 2026, an estimated $309K.
  • Paul Tudor Jones first reported a position in Keros Therapeutics in Q2 2022 and held it in 12 quarters.
  • Paul Tudor Jones's Keros Therapeutics position peaked at $1.15M in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.